Dr. Reddy's Launches Rituxan Generic
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced
You may also be interested in...
Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference
ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application
Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference
ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application
Indian Firms Look To Cash In On Growing Demand For Biosimilars
NEW DELHI - Increasing interest in the European Union and U.S. for biosimilar drugs has prompted Indian companies to actively explore these markets. Various estimates have predicted that the market for biosimilars could increase to $25 billion in Europe and $30 billion in the U.S. by 2015. Indian companies are looking to exploit such opportunities